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Abstract 
Inhibition of neuronal cyclooxygenase-2 (COX-2) and hence prostaglandin E2 (PGE2) synthesis by 
non-steroidal anti-inflammatory drugs has been suggested to protect neuronal cells in a variety of 
pathophysiological situations including Alzheimer’s disease and ischemic stroke. Ascorbic acid 
(vitamin C) has also been shown to protect cerebral tissue in a variety of experimental conditions, 
which has been attributed to its antioxidant capacity. In the present study, we show that ascorbic 
acid dose-dependently inhibited interleukin-1β (IL-1β)-mediated PGE2 synthesis in the human 
neuronal cell line, SK-N-SH.  Furthermore, in combination with aspirin, ascorbic acid augmented 
the inhibitory effect of aspirin on PGE2 synthesis. However, ascorbic acid had no synergistic effect 
along with other COX inhibitors (SC-58125 and indomethacin). The inhibition of IL-1β-mediated 
PGE2 synthesis by ascorbic acid was not due to the inhibition of the expression of COX-2 or 
microsomal prostaglandin E synthase (mPGES-1). Rather, ascorbic acid dose-dependently (0.1-100 
µM) produced a significant reduction in IL-1β-mediated production of 8-iso-prostaglandin F2α (8-
iso-PGF2α), a reliable indicator of free radical formation, suggesting that the effects of ascorbic acid 
on COX-2-mediated PGE2 biosynthesis may be the result of the maintenance of the neuronal redox 
status since COX activity is known to be enhanced by oxidative stress. Our results provide in vitro 
evidence that the neuroprotective effects of ascorbic acid may depend, at least in part, on its ability 
to reduce neuronal COX-2 activity and PGE2 synthesis, owing to its antioxidant properties. Further, 
these experiments suggest that a combination of aspirin with ascorbic acid constitutes a novel 
approach to render COX-2 more sensitive to inhibition by aspirin, allowing an anti-inflammatory 
therapy with lower doses of aspirin, thereby avoiding the side effects of the usually high dose aspirin 
treatment.  
Keywords: vitamin C, cyclooxygenase-2, oxidative stress, Alzheimer’s disease, stroke, reactive 
oxygen species, neuroinflammation, NSAIDs, 8-isoprostanes, prostaglandin E synthase 
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Introduction 
A large body of evidence implicates both brain inflammation and oxidative stress in the 
pathophysiological mechanisms contributing to the neuronal death seen in different neurological 
disorders including Alzheimer’s disease (AD), Parkinson’s disease and stroke (for a recent review, 
see Andersen, 2004). Inflammatory processes may contribute to the neurodegenerative process 
through mechanisms involving the release of pro-inflammatory cytokines, reactive oxygen species 
(ROS), nitric oxide (NO) and prostaglandins.  
 
Prostaglandins are produced by the enzymatic action of cyclooxygenase (COX). Two isoforms of 
COX have been described: COX-1 and COX-2 (Seibert et al., 1997). COX-1 is expressed 
constitutively in many organs and contributes to the synthesis of prostanoids involved in normal 
cellular functions (Seibert et al., 1997). COX-2 is expressed in several cell types after inflammatory 
stimulation including monocytes and macrophages (Pairet and Engelhardt, 1996). In the CNS, COX-
2 is expressed under normal conditions in neurons of the cortex, hippocampus and amygdala 
(Yamagata et al., 1993; Chang et al., 1996), and is mainly linked to synaptic activity (Kaufmann et al., 
1996). Seizure activity and spreading depression induce COX-2 expression while tetrodotoxin or 
blockade of N-methyl-D-aspartate (NMDA) receptors with MK-801 reduce neuronal COX-2 
expression (Yamagata et al., 1993; Miettinen et al., 1997). 
 
COX-2 has become the focus of attention because it is the rate-limiting enzyme involved in 
arachidonic acid metabolism, thereby generating prostaglandins and thromboxanes, molecules that 
play important roles in supporting and sustaining the inflammatory response (Vane et al., 1998), and 
the induction of COX-2 results in an inflammatory cascade accompanied by formation of ROS. 
 
In both, AD and cerebral ischemia, neuronal COX-2 expression may exaggerate CNS damage. In AD, 
elevated expression of COX-2 mRNA and protein has been reported (Oka and Takashima, 1997; 
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Pasinetti and Aisen, 1998). COX-2 protein expression may be elevated in hippocampal neurons in AD 
although findings have been contradictory (Chang et al., 1996; Ho et al., 1999). In animal models of 
hypoxia and in human ischemia, COX-2 is abundantly expressed in neurons, astroglia and microglia 
(Ohtsuki et al., 1996). Elevated neuronal COX-2 expression in CNS pathology may not depend on 
synaptic activity but on other inducers of COX-2 such as the proinflammatory cytokine interleukin-1β 
(IL-1β) (Harris et al., 1996; Fiebich et al., 2000b; Touzani et al., 2002). In transgenic animals 
overexpressing COX-2, glutamatergic excitotoxicity is enhanced (Kelley et al., 1999). COX-2 deficient 
mice vice versa show a reduced neuronal vulnerability to ischemia and excitotoxicity (Iadecola et al., 
2001).  
 
Several epidemiological studies suggested a strong protective effect of nonsteroidal anti-
inflammatory drugs (NSAIDs) against the development of AD (in t'Velt et al., 2001). The anti-
inflammatory, analgesic and antipyretic actions of NSAIDs such as aspirin are thought to be mainly 
due to an inhibition of COX-2 leading to a lowered prostaglandin synthesis (Pairet and Engelhardt, 
1996).  
 
Ascorbic acid (vitamin C) is an antioxidant vitamin which accumulates in the brain from the blood 
supply and is maintained at high concentrations in both neuronal and glial cells (Rebec and Pierce, 
1994; Rice and Russo-Menna, 1998). Ascorbic acid serves as a neuromodulator in normal brain 
functioning and as a neuroprotective agent in various conditions of oxidative stress (Grunewald, 
1993). The neuroprotective action of ascorbic acid has been mainly attributed to its antioxidant 
capacity.  
 
In the present study, we tested a broader field of possible functions of ascorbic acid and investigated 
whether ascorbic acid is able to inhibit COX-2-mediated PGE2 synthesis and may augment the 
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inhibitory effect of aspirin on PGE2 synthesis. As a model system, we used the human neuronal cell 
line SK-N-SH. In these cells, COX-2 and subsequent prostaglandin synthesis can be induced by IL-
1β, a cytokine which is involved in neuroinflammation (Harris et al., 1996; Rothwell and Luheshi, 
2000; Fiebich et al., 2000b; Touzani et al., 2002). The present study was prompted by our previous 
findings, which showed a potent inhibitory effect of ascorbic acid on PGE2 production in 
lipopolysaccharide (LPS)-activated primary rat microglial cells (Fiebich et al., 2003).  
 
Materials and Methods  
Materials 
Human IL-1β, which is effective on mouse and human cells, was purchased from Roche Diagnostics 
(Mannheim, Germany). L-Ascorbic acid, Dehydro-L-(+)-Ascorbic acid (DHA), Trolox C (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid), indomethacin, and aspirin (acetylsalicylic acid) were 
obtained from Sigma-Aldrich (Deissenhofen, Germany). The highly selective COX-2 inhibitor SC-
58125 (1-[(4-methysufonyl)phenyl]-3-tri-fluoromethyl-5-(4-fluorophenyl) pyrazole) and the highly 
selective COX-1 inhibitor SC-560 (5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-
pyrazole) were obtained from Cayman Chemical (Ann Arbor, Michigan, USA). All compounds, used 
at the given concentrations, do not affect the viability of the cells as observed through the CellTiter-
Glo® luminescent cell viability assay kit (Promega, Mannheim, Germany), which measures metabolic 
ATP levels (data not shown). 
 
Cell culture 
The human neuroblastoma cell line SK-N-SH was obtained from the American Type Culture 
Collection (HTB-11, Rockville, USA) and was grown in MEM-Earle's medium (PAA, Cölbe, 
Germany), which does not contain any ascorbic acid. Medium was supplemented with 5% fetal calf 
serum (FCS) (PAN, Aidenbach, Germany), 2 mM L-glutamine, 1 mM sodium pyruvate, 40 units/ml 
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penicillin/streptomycin (all purchased from PAA Laboratories, Cölbe, Germany), 0.4% MEM vitamins 
(not containing ascorbic acid) and 0.4% MEM non-essential amino acids (both purchased from 
Invitrogen GmbH, Karlsruhe, Germany). Confluent monolayers were passaged routinely by 
trypsinization. Cells were plated for protein and RNA analysis in 6-well plates (2.8 x 105 cells/well) and 
for determination of PGE2 and 8-iso-prostaglandin F2α (8-iso-PGF2α) in 24-well plates (9 x 104 
cells/well). Cultures were grown at 37°C in 5% CO2 until 80% confluence, and the medium was 
changed the day before treatment.  
 
Prostaglandin E2 (PGE2) Enzyme immunoassay 
SK-N-SH cells were plated in 24-well cell culture plates and pre-incubated for 30 min with the 
inhibitors to be tested. Thereafter, cells were treated with IL-1β (10 U/ml) for 24 h. Supernatants 
were then used for the determination of PGE2. Supernatants were harvested, centrifuged at 10,000 x 
g for 10 min and levels of PGE2 in the media were measured by enzyme immunoassay (EIA) 
(Biotrend, Köln, Germany) according to the manufacturer’s instructions. Standards from 39 to 2500 
pg/ml were used; sensitivity of the assay is 36.2 pg/ml.  
 
Cyclooxygenase (COX) activity assay 
To determine any direct inhibitory effect of ascorbic acid, DHA or the combination of aspirin with 
ascorbic acid on COX enzymatic activity, an arachidonic acid assay was performed (Fiebich et al., 
2003). Briefly, SK-N-SH cells were plated in 24-well cell culture plates and pre-incubated with IL-
1β (10 U/ml) for 24 h. Medium was then changed to a serum-free medium. Inhibitors were added 
for 15 min, and arachidonic acid (15 µM final concentration) was supplemented for another 15 min. 
Supernatants were then collected for the determination of PGE2 as described above.  
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Polyacrylamide gel electrophoresis and Western blot analysis 
SK-N-SH cells were left untreated or treated with IL-1β (50 U/ml) in the presence or absence of 
ascorbic acid (100 µM), aspirin (100 µM) and a combination of both (each at 100 µM) for 24 h. 
Cells were then washed with Dulbecco’s phosphate buffered saline (Cell Concepts GmbH, Umkirch, 
Germany) and lysed in 1.3 % SDS (sodium dodecyl sulfate) containing 100 µM orthovanadate 
(Laemmli, 1970). Lysates were homogenized by repeated passage through a 26-gauge needle. 
Protein contents were measured using the bicinchoninic acid method (BCA protein determination kit 
from Pierce, distributed by KFC Chemikalien, München, Germany) according to the manufacturer’s 
instructions using bovine serum albumin (BSA, Sigma) as a standard (ranging from 2 to 40 µg/µl; 
optical density read at 570 nm). Before electrophoresis, 0.1% bromophenol blue and 10 mM DTT 
were added to the samples and incubated at 95°C for 5 min before loading. For western blotting, 40 
µg of protein from each sample was subjected to SDS-PAGE (polyacrylamide gel electrophoresis) 
on a 7.5% gel under reducing conditions. Proteins were then transferred onto a polyvinylidene 
fluoride (PVDF) membrane (Millipore, Bedford, MA, USA) by semi-dry blotting. The membrane 
was blocked overnight at 4°C using Rotiblock (Roth, Karlsruhe, Germany) and for another hour at 
room temperature before incubation with the primary antibody. Primary antibodies were goat anti-
COX-2 (M-19) or goat anti-COX-1 (M-20) obtained from Santa Cruz Biotechnology (Heidelberg, 
Germany). Both antibodies were diluted 1:500 in Tris-buffered saline (TBS, 50 mM, pH 8.0) 
containing 0.1% Tween 20 (Merck, Darmstadt, Germany) and 1 % bovine serum albumin (BSA, 
Sigma). Membranes were incubated with the corresponding primary antibody for 2 h at room 
temperature. After extensive washing (three times for 15 min each in TBS containing 0.1% Tween 
20), proteins were detected with horse radish peroxidase-coupled rabbit anti-goat IgG (Santa Cruz, 
1:100,000) using chemiluminescence (ECL) reagents (Amersham Pharmacia Biotech, Freiburg, 
Germany). Quantification of the Western Blots was performed using ScanPack 3.0 software 
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(Biometra, Göttingen, Germany). Equal protein loading and transfer were assessed by subjection of 
each sample to a Western blot for actin (rabbit anti-actin antibody diluted 1:1000, obtained from 
Sigma, Saint Louis, MO, USA). All western blot experiments were carried out at least three times.  
 
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted using the guanidine isothiocyanate method according to Chomczynski and 
Sacchi (Chomczynski and Sacchi, 1987). For RT-PCR, 2 µg of total RNA was reverse transcribed 
using Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Promega, Mannheim, 
Germany), RNase Inhibitor rRNasin® (Promega), dNTP master mix (Invitek, Berlin, Germany) and 
random hexamer primers (Promega). PCR was carried out using Taq DNA polymerase (Promega), 
dNTP master mix (Invitek, Berlin, Germany) and the following primers: human microsomal 
prostaglandin E synthase-1, mPGES-1 (forward:  5’-CTCTGCAGCACGCTGCTGG-3’, reverse: 5’-
GTAGGTCACGGAGCGGATGG-3’, annealing temperature 65°C, 35 cycles, amplicon size: 338 
bp). Equal equilibration was determined using human β-actin primers (forward: 5’-
ATCTGGCACCACACCTTCTACAATGAGCTGCG-3’, reverse: 5’-
CGTCATACTCCTGCTTGCTGATCCACATCTGC-3’, 60°C, 30 cycles, product length: 838 bp). 
PCR products were separated electrophoretically on a 2% agarose gel. Potential contamination by 
genomic DNA was controlled by omitting reverse transcriptase and using β-actin primers in the 
subsequent PCR amplification. Only RNA samples showing no bands after this procedure were used 
for further investigation. Primers were designed using the Primer 3 software developed by the 
Whitehead Institute for Biomedical Research (http://frodo.wi.mit.edu/primer3/primer3_code.html) 
and synthesized through an in-house facility (Dr. Gabor Igloi, Institute for Biology III, Freiburg, 
Germany).  
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Determination of 8-iso-prostaglandin F2α (8-iso-PGF2α) 
SK-N-SH cells were pre-treated for 30 min with different concentrations of ascorbic acid (0.1-100 
µM), DHA (0.1-100 µM) or Trolox C (10 and 100 µM), or with aspirin (0.1-100 µM; alone or in 
combination with 10 µM ascorbic acid), indomethacin or SC-58125. After 30 min pre-stimulation, 
cells were stimulated with 10 U/ml IL-1β for 24 h. Supernatants were harvested and the levels of 8-
iso-PGF2α were measured by an enzyme immunoassay according to the manufacturer’s instructions 
(Cayman Chemicals, Ann Arbor, MI, USA). The standards were used in the range of 3.9 to 500 
pg/ml (detection limit of 5 pg/ml).  
 
Data Analysis  
Data from at least 3 experiments with 2-3 wells per concentration (n=8-9) were used for data 
analysis. Statistical analysis was done by the Institut für Biochemische Analysen und 
Methodenentwicklung GbR (Freiburg, Germany). Original data were converted into %-values of IL-
1β control and mean ± S.D. calculated. Inhibitor concentration at which 50% inhibition is observed 
(defined as IC50) was calculated by computerized non-linear regression analysis. In the figures, a 
regression curve was adjusted to the calculated mean values. In some experiments, data are 
presented as mean ± S.D. and values were compared using t-test (two groups) or one-way ANOVA 
with post-hoc Student-Newman-Keuls test (multiple comparison).  
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Results 
The effects of ascorbic acid and aspirin on PGE2 production were investigated in the human 
neuroblastoma cell line SK-N-SH. Basal production of PGE2 in these cells (i.e. during unstimulated 
conditions) was 138 pg/ml ± 101 pg/ml (mean ± S.D.). The addition of increasing amounts of IL-1β 
led to a dose-dependent increase in COX-2 protein expression with the concomitant PGE2 
biosynthesis, which is maximal at 10-50 U/ml IL-1β as shown in our previous report (Fiebich et al., 
2000b). After 24 h (IL-1β, 50 U/ml), PGE2 production in SK-N-SH cells increased approximately 4-
fold to 637 pg/ml ± 145 pg/ml (mean ± S.D.). 
 
As expected, aspirin dose-dependently inhibited IL-1β-induced PGE2 synthesis with an IC50 of 2.32 
µM (Fig. 1A). Ascorbic acid alone also caused a dose-dependent inhibition of IL-1β-induced PGE2 
biosynthesis, starting at 1 µM (20% inhibition). The maximal effect was an inhibition of 
approximately 62.5% at a dose of 100 µM with an IC50 of 6.76 µM (Fig. 1A). In further 
experiments, increasing concentrations of ascorbic acid were added to aspirin to investigate a 
possible additive effect of both substances. As shown in Fig. 1A, a possible synergistic effect of 
ascorbic acid (10, 30 and 100 µM) was observed, mainly in combination with low doses of aspirin 
(10 and 100 nM). The combination of aspirin with 10 µM ascorbic acid resulted in a significant 
decrease in the IC50 for aspirin, going from 2.32 µM (aspirin alone) to 0.85 µM (Fig. 1A). At high 
doses of ascorbic acid (30 and 100 µM), the inhibitory effect of aspirin was potently enhanced 
resulting in an IC50 of 0.68 and 0.15 µM, respectively (Fig. 1A). Thus, in this system, ascorbic acid 
produced a synergistic action on aspirin-mediated inhibition of PGE2 production. In other words, the 
combination of aspirin and ascorbic acid (100 µM) was 15 times more potent than aspirin alone in 
inhibiting IL-1β-induced PGE2 synthesis in neuronal cells. Interestingly, Trolox C, an antioxidant 
used as control, potently reduced PGE2 production in SK-N-SH cells stimulated with IL-1β as 
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shown in Fig. 1B. The addition of indomethacin (a non-selective COX inhibitor used as control) 
completely prevented IL-1β-mediated PGE2 production (Fig. 1B), confirming our previous 
observations (Fiebich et al., 2000b).   
 
These initial results raised two main questions: 1) is the inhibitory effect of aspirin on PGE2 
production also potentiated by other antioxidants, and 2) does ascorbic acid synergize with other 
COX inhibitors?. In an attempt to respond to the first question, we conducted an experiment in 
which several doses of aspirin were combined with Trolox C (1 and 10 µM). As shown in Fig. 2, 
Trolox C (10 µM) also enhanced the inhibitory effect of aspirin on IL-1β-induced PGE2 synthesis in 
SK-N-SH cells. A clear example of this possible synergistic effect is observed at the lower dose: 
aspirin at 0.1 µM had no effect on IL-1β-mediated PGE2 production, but in combination with 10 µM 
Trolox C, a 47% inhibition was observed (p<0.01). Similar effects were also observed at higher 
doses of aspirin, ranging from 1 to 100 µM (Fig. 2). 
 
The answer to our second question is depicted in Fig. 3. We included other COX inhibitors in this 
experiment, and interestingly, we didn’t observe any additive effect of ascorbic acid on COX-
mediated PGE2 formation when combined with these compounds. As expected, the highly selective 
COX-2 inhibitor SC-58125 significantly reduced PGE2 production, but the combination of ascorbic 
acid with this compound had no further inhibitory effect on PGE2 synthesis (Fig. 3A). Similar 
results were found in the case of the non-selective COX inhibitor indomethacin (Fig. 3B).  
 
Since COX-2 expression is in part dependent on redox-sensitive transcriptional events (Fiebich et 
al., 2000b; Kim et al., 2000; Madrigal et al., 2003), and previous evidences indicate that ascorbic 
acid reduces COX-2 expression under some conditions (Sanchez-Moreno et al., 2003; Han et al., 
2004), we decided to investigate if ascorbic acid is able to affect COX-2 expression in our in vitro 
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model. Densitometric analysis of 3 independent Western blots revealed that ascorbic acid and aspirin 
alone or in combination (100 µM each) did not influence IL-1β-induced synthesis of COX-2 protein 
in SK-N-SH cells (Fig. 4A and 4B). The non-inducible COX-1 protein synthesis was not affected by 
IL-1β, ascorbic acid or aspirin (Fig. 4A and 4B).  
 
In our next experiments, we explored an alternative or additional possible effect of ascorbic acid, its 
oxidized form DHA, and the combination of aspirin and ascorbic acid on the expression of the 
inducible prostaglandin E synthase (mPGES-1), an important enzyme downstream of COX in the 
biosynthesis of PGE2. Stimulation of various cultured cells with pro-inflammatory stimuli leads to a 
marked elevation of mPGES-1, often with concomitant induction of COX-2 (Jakobsson et al., 1999; 
Murakami et al., 2000; Mancini et al., 2001; Murakami et al., 2002). In this study, we show for the 
first time a marked upregulation in the expression of mPGES-1 in SK-N-SH cells exposed to IL-
1β (10 U/ml) for 4 h (Fig. 5). This pronounced effect of IL-1β was not prevented by any 
concentration of ascorbic acid, DHA, the combination of aspirin with ascorbic acid or either 
compound alone, as depicted in Fig. 5.  
 
Considering that a mechanism involving reduction of COX-1 or COX-2 protein expression cannot 
explain the inhibitory effects of ascorbic acid on IL-1β-induced PGE2 synthesis, and its possible 
synergistic effect in combination with aspirin (Fig. 4), we decided to investigate whether ascorbic 
acid might be acting through direct inhibition of COX activity, and/or directly potentiating the 
inhibitory action of aspirin. Table 1 shows the findings from the COX enzymatic activity assay. At 
doses of 10 and 100 µM, aspirin produced a 23 and 48 % inhibition of COX activity, respectively. 
The combination of aspirin with ascorbic acid (10 and 100 µM) did not further decrease aspirin-
mediated COX inhibition, as reflected in the levels of PGE2. Similarly, ascorbic acid was unable to 
directly inhibit COX activity in this assay (Table 1). We also checked if the oxidized metabolite of 
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ascorbic acid, DHA, could modify COX catalysis. Similar to what was found for ascorbic acid, 
DHA failed to inhibit COX activity (data not shown).  
 
Results from the COX activity assay showed that ascorbic acid is unable to directly inhibit COX 
activity (Table 1). Control experiments with indomethacin and SC-58125 (a COX-2 selective 
inhibitor) showed a potent inhibitory effect of both compounds in this COX enzymatic assay (Table 
1), confirming the validity of this system to study the inhibitory properties of ascorbic acid on 
neuronal COX activity. A control experiment with the highly selective COX-1 inhibitor SC-560 (10 
and 100 nM) showed that COX-1 inhibition fails to significantly reduce PGE2 in this assay, as 
presented in Table 1.  
 
After having excluded the possibility that the effects of ascorbic acid in the present study were 
mediated by downregulation of the expression of key enzymes involved in PGE2 production (COX-
1/2, mPGES-1), and taking into account that COX enzymatic activity increases under conditions of 
oxidative stress due to the activation of COX by hydroperoxides (Hemler and Lands, 1980; Kulmacz 
and Lands, 1983), we then studied the effects of ascorbic acid and its oxidized metabolite DHA on 
the formation of 8-iso-PGF2α, an index of oxidant stress-mediated production of lipid 
hydroperoxides / ROS. 8-isoprostanes are formed in response to free radical attack on arachidonic 
acid on membrane phospholipids and are considered as a reliable and highly sensitive measure of 
reactive oxygen species (ROS) formation (Pratico et al., 1998). We also investigated if the 
simultaneous incubation with ascorbic acid and aspirin produces an additive effect on IL-1β-induced 
8-iso-PGF2α production.  
 
IL-1β (10 U/ml) produced a dramatic increase in 8-iso-PGF2α concentrations in the culture media 
collected from SK-N-SH cells treated for 24 h with this pro-inflammatory cytokine (Fig. 6), which is 
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in line with findings of a previous study in neuronal cells (Igwe et al., 2001). Interestingly, ascorbic 
acid dose-dependently reduced IL-1β-induced oxidative stress as shown in Fig. 6A. Only the highest 
dose of DHA (100 µM) was able to reduce 8-iso-PGF2α formation by ~50%. Treatment with the 
antioxidant Trolox C potently reduced IL-1β-mediated ROS formation, as evidenced by the 
maintenance of 8-iso-PGF2α concentrations to basal levels with the highest dose (100 µM) of Trolox 
C (Fig. 6A).  
 
Aspirin dose-dependently inhibited the formation of 8-iso-PGF2α, an effect that was potentiated by 
ascorbic acid at the highest doses of aspirin tested (10 and 100 µM), as shown in Fig. 6B. The effect 
of the combination of low doses (0.1 and 1 µM) of aspirin and ascorbic acid on 8-iso-PGF2α, was 
mainly due to the effects of ascorbic acid since no statistically significant differences (p>0.05) were 
observed among low doses (0.1 and 1 µM) of aspirin plus ascorbic acid and ascorbic acid alone (Fig. 
6B). Nevertheless, when higher doses of aspirin were tested, the combination of this COX inhibitor 
with ascorbic acid produced a significant reduction in 8-iso-PGF2α, which was statistically different 
(p<0.05) from ascorbic acid alone (Fig. 6B).  
 
Since COX activity is associated to the formation of free radicals (Kukreja et al., 1986; Jiang et al., 
2004) and there is a dramatic increase in COX-2 enzymatic activity in neuronal cells upon 
stimulation with the pro-inflammatory cytokine IL-1β, we checked the possibility that COX 
inhibition might reduce neuronal oxidative stress. Interestingly, our experiments demonstrated  
potent inhibitory effects of the highly COX-2 inhibitor SC-58125 and the non-selective COX 
inhibitor indomethacin on 8-iso-PGF2α production in IL-1β-stimulated neuronal cells (Fig. 6C).  
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Discussion  
 
This study investigated, for the first time, the inhibitory effect of ascorbic acid alone or in 
combination with aspirin on PGE2 synthesis in neuronal cells, using the human neuronal cell line 
SK-N-SH. Our results demonstrate that ascorbic acid mediates moderate inhibition of neuronal 
PGE2 biosynthesis and that in combination with aspirin leads to a super-additive and almost 
complete inhibition of COX-2-mediated PGE2 formation. These findings are in line with our 
previous data in LPS-activated primary microglial cells, where a synergistic inhibitory effect of 
ascorbic acid and aspirin on COX-2-mediated PGE2 production was observed (Fiebich et al., 2003).  
 
Cultures of the human neuroblastoma cell line SK-N-SH are an useful model to study the induction 
and inhibition of neuronal prostaglandin synthesis, since they express mPGES-1 and COX-2 mRNA 
and protein and show PGE2 production upon stimulation with IL-1β (Fiebich et al., 2000b). We have 
previously demonstrated that IL-1β-mediated PGE2 production is mainly dependent on the activity 
of COX-2, based on the potent inhibitory effects of highly selective COX-2 inhibitors on IL-1β-
induced PGE2 biosynthesis (Fiebich et al., 2000b). Moreover, the failure of the highly selective 
COX-1 inhibitor SC-560 to reduce COX activity (Table 1) provides further support to our previous 
observations, indicating the key contribution of COX-2, rather than COX-1, to the PGE2 production 
induced by IL-1β in SK-N-SH cells.  
 
Reduction of PGE2 by ascorbic acid was not related to modification of COX-1 protein expression, 
which is not induced by IL-1β in SK-N-SH cells (Fig. 4A and Fiebich et al., 2000b), and which 
basal levels are not affected by ascorbic acid (Fig. 4A). We did not find a reduction in the amount of 
COX-2 protein when adding ascorbic acid to the cultures, which is in agreement with findings in a 
macrophage cell line, where no effect of ascorbic acid and aspirin on COX-2 expression was shown 
(Abate et al., 2000). Similarly, ascorbic acid alone or in combination with aspirin failed to modify 
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IL-1β-induced mPGES-1 expression. Although previous studies have shown that mPGES-1 is the 
most important isozyme involved in PGE2 production under inflammatory conditions (Murakami et 
al., 2000; Mancini et al., 2001; Murakami et al., 2002), we can not rule out that the effects observed 
in the present study result from changes in the expression of other PGES isoforms (e.g., cPGES or 
mPGES-2) following incubation of SK-N-SH cells with IL-1β in the presence of ascorbic acid 
and/or aspirin. 
 
Our data demonstrate that ascorbic acid inhibits COX-2-mediated PGE2 production. One possibility 
is that ascorbic acid acts on the catalytic site of COX-2, which is the primary mechanism of action 
of aspirin-like drugs (Luong et al., 1996). Nevertheless, we excluded this possibility in the present 
study since neither ascorbic acid nor its oxidized metabolite DHA was able to inhibit neuronal COX 
enzymatic activity (Table 1). This finding is in contrast with our previous observations on the direct 
inhibitory effects of ascorbic acid on COX-2 activity in LPS-treated primary rat microglia (Fiebich 
et al., 2003). The apparent discrepancies between these studies might be due to different cell type 
(primary rat microglia vs. human neuroblastoma cell line). However, up to now, inhibition of the 
catalytic site of COX-2 has not been shown to be cell type specific for any drug. In addition, there 
might be differences in the expression of ascorbic acid transporters between microglial and neuronal 
cells, although further studies need to be performed to address this issue.  
 
The effects of ascorbic acid on COX-2-mediated PGE2 production may be mediated through its 
interaction with the peroxidation site of COX-2, which has also been proposed for paracetamol 
(Fiebich et al., 2000a; Boutaud et al., 2002). Most interestingly, the indirect inhibition of COX-2 by 
reducing the higher oxidative states has been shown to be cell type specific which may not only 
explain the cell type selective effects of paracetamol (Boutaud et al., 2002), but also the effects of 
the antioxidants ascorbic acid and Trolox C observed in the present study (Fig. 1). This notion is 
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supported by our findings that ascorbic acid as well as Trolox C dose-dependently reduced IL-1β-
induced neuronal production of 8-iso-PGF2α and PGE2 (Figs. 1 and 6A). There is a large body of 
experimental evidence indicating that COX catalysis involves radical intermediates, which is further 
supported by the results showing that COX activity is reduced by a variety of antioxidants 
(Takeguchi and Sih, 1972; Vanderhoek and Lands, 1973; Hemler and Lands, 1980; Ciuffi et al., 
1996; Jiang et al., 2000; Beharka et al., 2002). The present finding that the selective COX-2 
inhibitor SC-58125 showed a high potency in reducing IL-1β-mediated formation of 8-iso-PGF2α 
(Fig. 6C), suggests that COX-2 activity is one of the major sources of ROS in neuroinflammation. 
Similarly, our recent results in LPS-activated microglia also showed a COX-2-dependent formation 
of 8-iso-PGF2α (Akundi et al., 2005). Although isoprostanes are non-enzymatic products formed by 
free radical attack on arachidonic acid, in vitro and in vivo evidences suggest that 8-iso-PGF2α could 
in part derive from COX activity (Pratico et al., 1995; Pepicelli et al., 2002). This is further 
supported by in vivo findings on the contribution of COX-2 to oxidative damage during brain 
ischemia (Candelario-Jalil et al., 2003a, 2003b), and traumatic brain injury (Tyurin et al., 2000), 
conditions in which the neuroinflammatory mechanisms play a key role in neuronal damage.  
 
Our present observations on the effects of the antioxidants ascorbic acid and Trolox C as well as the 
COX inhibitors indomethacin and SC-58125 on PGE2 production and free radical formation suggest 
that ROS are partly responsible for the regulation of COX-2-mediated PGE2 production in IL-1β-
stimulated neuronal cells. This might lead to a positive feedback mechanism in which COX-2 
activity is induced by ROS, but at the same time COX-2 activity modulates the cellular redox status 
by further increasing ROS formation. 
 
Although we investigated several possible mechanisms in an effort to explain the synergistic effects 
of the combination of ascorbic acid and aspirin on the reduction of PGE2 in neuronal cells, the exact 
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mechanism of such interaction is not completely clear, especially due to the fact that ascorbic acid 
did not synergize with other COX inhibitors used as controls (Fig. 3). This is a completely 
unexpected finding. The reason for the possible synergistic effects observed in this study with the 
combination of antioxidants (ascorbic acid or Trolox C) and aspirin (Figs. 1 and 2), but not with 
other NSAIDs, is probably the result of more complex redox-sensitive mechanisms involved in the 
particular interaction of aspirin with COX.  
 
One important difference between aspirin and the other COX inhibitors used in our study is its 
unique mechanism of action, which involves the covalent modification of COX. The interactions of 
aspirin with COX isoforms are particularly interesting. Aspirin irreversibly inhibits COX-1 by 
acetylating an active site serine which resides in the arachidonic acid binding pocket (DeWitt et al., 
1990). Acetylation appears to cause steric hindrance to arachidonic acid binding, thereby blocking 
COX-1 activity (DeWitt et al., 1990). Aspirin also causes a time-dependent acetylation of serine 516 
of the human COX-2, converting this enzyme to a form which is still capable of oxygenating 
arachidonic acid leading to the synthesis of 15-R-hydroxyeicosatetraenoic acid (15-R-HETE) instead 
of PGH2 (Lecomte et al., 1994). Thus, the loss of cyclooxygenase activity in aspirin-treated COX-2 
is accompanied by an increase in lipoxygenase activity (Lecomte et al., 1994; Xiao et al., 1997). 
Unlike other NSAIDs, aspirin does not influence the peroxidase activity of COX-2 (Xiao et al., 
1997; Smith et al., 2000), which converts PGG2 into PGH2. Therefore, after aspirin treatment, the 
unchecked peroxidase activity of COX-2 can continue to generate free radical species and PGH2 
(Smith and Marnett, 1991; Mancini et al., 1997; Xiao et al., 1997). At low doses of aspirin, which 
are known to more effectively inhibit COX-1 rather than COX-2 (Demasi et al., 2000), large 
amounts of PGG2 (formed by the cyclooxygenase activity of COX-2) are then converted into PGH2 
by the peroxidase activity of COX-2, and further metabolized by the terminal prostaglandin 
synthases. At this point, antioxidants through a mechanism involving maintenance of the redox 
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status, could indirectly reduce the peroxidase activity of COX-2, with the concomitant reduction of 
PGE2 formation, as observed in our study (Figs. 1 and 2). This notion is further supported by the fact 
that the synergistic effects of ascorbic acid and aspirin are much more evident at low doses of 
aspirin (Fig. 1). When present at higher doses, aspirin-mediated acetylation of COX-2 results in the 
conversion of PGG2 into 15-R-HETE by the lipoxygenase activity of the acetylated COX-2.  
 
Unlike aspirin, the other NSAIDs tested in our investigation act through a mechanism involving 
competition with arachidonic acid for binding to COX (DeWitt, 1999; Smith et al., 2000), thus 
producing an inhibition of both activities of COX (cyclooxygenase and peroxidase). This probably 
explains why ascorbic acid does not synergize with the other NSAIDs.  
 
Results presented in Fig. 3, which show the failure of ascorbic acid to potentiate the inhibitory 
effects of other NSAIDs, exclude the possibility that the effects observed with the combination of 
ascorbic acid and aspirin might be related to reduction in the availability of arachidonic acid or 
enhancement of the catabolism of PGE2 mediated by ascorbic acid.  
 
It is noteworthy that ascorbic acid reduced IL-1β-mediated formation of ROS and PGE2 in neuronal 
cells since this cytokine is one of the key player of brain as well as peripheral inflammation (for 
reviews see Rothwell and Luheshi, 2000; Basu et al., 2004; Braddock and Quinn, 2004). Although 
DHA has no antioxidant capacity by itself, it was able to reduce 8-isoprostane formation at the 
highest dose (Fig. 6A). A plausible explanation for this finding might be that DHA is recycled 
intracellularly to ascorbic acid and that it is the latter which might produce the observed inhibitory 
effect. DHA is physiologically formed either directly or via the disproportionation of the ascorbyl 
radicals and this oxidised form of vitamin C is directly converted to ascorbic acid either by direct 
chemical reaction with reduced glutathione (GSH), which is believed to be the major pathway for 
ascorbic acid recycling (Winkler et al., 1994), or by NAD(P)H-dependent enzymes such as 
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thioredoxin reductase and GSH-dependent DHA reductase (Wells and Xu, 1994; May et al., 1997; 
May, 2002). Although DHA can be recycled into ascorbic acid, it is rapidly degraded/metabolized; 
thus resulting in lesser effective concentration of ascorbic acid in the cell than the tested dose.  
 
The inhibitory effects of ascorbic acid alone and the possible synergistic effects when combined 
with aspirin might be of clinical relevance for diseases of the CNS when neuronal COX-2 inhibition 
is the therapeutic target. Oral dosing with ascorbic acid results in plasma concentrations that reach a 
plateau of 80 µM, and intracellular concentrations reach a plateau in the range of 1.4 to 3.4 mM with 
a dose of 200 mg per day (Levine et al., 1996). Addition of ascorbic acid, which is extracted from 
the blood stream and concentrated in the CNS to high levels (Rice and Russo-Menna, 1998), may 
augment the inhibition of neuronal COX-2 by aspirin especially in elderly people, in which cerebral 
levels of ascorbic acid may decline (Svensson et al., 1993; Miele and Fillenz, 1996; Rice and Russo-
Menna, 1998).   
 
Inhibition of the neuronal COX-2 enzyme activity may be a therapeutic target in AD and cerebral 
ischemia (Iadecola and Alexander, 2001; Pasinetti, 2001; Hull et al., 2002; Candelario-Jalil et al., 
2004). Prospective epidemiological data repeatedly confirmed a strong protective effect of NSAIDs 
(in t'Velt et al.,  2001) and  a small protective effect of ascorbic acid (Engelhart et al., 2002) against 
the development of AD. Clinical studies with NSAIDs for inhibiting COX in the CNS have mainly 
been hampered by peripheral toxicity (Rogers et al., 1993). After 1995, a new class of selective 
COX-2 inhibitors (e.g., rofecoxib, celecoxib) was widely marketed in an effort to reduce side effects 
associated to the use of non-selective COX inhibitors. However, recent evidences indicate that 
selective COX-2 inhibitors are unsafe for clinical use, with patients having an increased risk of 
cardiovascular events (Juni et al., 2004). Preferential inhibition of neuronal COX-2 by addition of 
ascorbic acid to a lower dose of aspirin may be helpful to overcome peripheral side effects. 
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Furthermore, recent studies show that ascorbic acid attenuates aspirin-induced gastric damage 
(Brzozowski et al., 2001; Pohle et al., 2001; Becker et al., 2003; Dammann et al., 2004; Konturek et 
al., 2004).  
 
In summary, the key finding of this investigation is our observation that ascorbic acid substantially 
enhances COX-2 inhibition by aspirin. At low aspirin doses that only partially reduced PGE2 
formation, simultaneous addition of ascorbic acid virtually abolished IL-1β-induced PGE2 
production. This finding may provide an important in vitro evidence for clinical observations 
showing that concurrent administration of ascorbic acid allows for dose reduction of aspirin without 
reducing its therapeutic efficacy. This study provides the first evidence for a possible synergism of 
aspirin and ascorbic acid in neuronal cells, which may have important implications for the treatment 
of neuroinflammatory conditions. According to the results presented here, co-administration of 
ascorbic acid constitutes a novel approach to render COX-2 more sensitive to inhibition by aspirin. 
Thus, anti-inflammatory therapy might be successful with lower doses of aspirin when combined 
with ascorbic acid, thereby avoiding the side effects of the usually required high dose aspirin 
treatment, and adding the antioxidant benefits of ascorbic acid.  
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Table 1 
Effects of ascorbic acid alone or in combination with aspirin on COX enzymatic activity in SK-N-
SH cells.  
Treatment PGE2 (% of IL-1β + 
Arachidonate Control) 
Effect of ASA and the combination of ASA and Ascorbic acid 
on COX enzymatic activity 
 
Control  0.4 ± 0.2 
Control + Arachidonate 15 µM 4.1 ± 1.8 
IL-1β (10 U/ml) without Arachidonate  7.5 ± 1.8 
IL-1β (10 U/ml) + Arachidonate 15 µM 100 ± 9.6 
IL-1β  + Arachidonate + ASA 1 µM 91.0 ± 9.2 
IL-1β  + Arachidonate + ASA 1 µM + Ascorbic acid 10 µM 81.4 ± 13.4 
IL-1β  + Arachidonate + ASA 1 µM + Ascorbic acid 100 µM 98.3 ± 3.8 
IL-1β  + Arachidonate + ASA 10 µM  77.3 ± 7.2* 
IL-1β  + Arachidonate + ASA 10 µM + Ascorbic acid 10 µM 80.1 ± 5.0*, § 
IL-1β  + Arachidonate + ASA 10 µM + Ascorbic acid 100 µM 84.0 ± 1.8*, § 
IL-1β  + Arachidonate + ASA 100 µM  52.1 ± 2.8** 
IL-1β  + Arachidonate + ASA 100 µM + Ascorbic acid 10 µM 56.3 ± 6.7**, § 
IL-1β  + Arachidonate + ASA 100 µM + Ascorbic acid 100 µM 58.8 ± 5.9**, § 
Effect of Ascorbic acid on COX enzymatic activity  
IL-1β  + Arachidonate + Ascorbic acid 10 µM 86.4 ± 13.4 
IL-1β  + Arachidonate + Ascorbic acid 100 µM 89.1 ± 18.3 
Effect of COX inhibitors (control experiment)  
IL-1β  + Arachidonate + SC-58125 0.1 µM 46.4 ± 4** 
IL-1β  + Arachidonate + SC-58125 1 µM 33.7 ± 3.9** 
IL-1β  + Arachidonate + Indomethacin 0.1 µM 10.6 ± 5.9*** 
IL-1β  + Arachidonate + Indomethacin 1 µM 1.5 ± 1.3*** 
IL-1β  + Arachidonate + SC-560  10 nM  99.9 ± 7.6 
IL-1β  + Arachidonate + SC-560  100 nM 86.1 ± 15 
 
Data are expressed as mean ± S.D. Cells were either left untreated or were stimulated with IL-1β (10 
U/ml) for 24 h. After removal of medium, cells were treated with different concentrations of the 
compound for 30 min in absence or presence of arachidonic acid. PGE2 in the supernatants was 
determined by an enzyme immunoassay as described in Materials and Methods. *p<0.05, **p<0.01 
and ***p<0.001 with respect to IL-1β + Arachidonate control. §p>0.05, no statistically significant 
difference with respect to the corresponding dose of aspirin alone.  
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Captions for Figures 
 
Fig. 1. Inhibitory effects of ascorbic acid (ASC) and aspirin (ASA) (Panel A) and Trolox C and 
Indomethacin (Panel B) on prostaglandin E2 synthesis in IL-1β-stimulated human SK-N-SH cells. 
Cells were pre-incubated with the inhibitors at the indicated concentrations for 30 min and 
subsequently treated with IL-1β (10 U/ml) for 24 h. PGE2 in the supernatants was measured by an 
enzyme immunoassay as described in Materials and Methods. Data are expressed as mean ± S.D. In 
Fig. 1A, the label of the X axis refers to the concentration of either aspirin or ascorbic acid when 
each drug is used alone, and at the same time, the X axis refers to aspirin concentration when used in 
combination with the given dose of ascorbic acid, as explained in the inset legend. *p<0.05 and 
**p<0.01 with respect to IL-1β-treated control.  
 
Fig 2.  The potent antioxidant Trolox C, a synthetic analogue of α-tocopherol, enhances the 
inhibitory effect of aspirin on PGE2 production following stimulation with IL-1β in neuronal cells. 
Cells were pre-incubated with the inhibitors at the indicated concentrations for 30 min and 
subsequently treated with IL-1β (10 U/ml) for 24 h. PGE2 in the supernatants was measured by an 
enzyme immunoassay as described in Materials and Methods. *p<0.05 with respect to IL-1β-treated 
control. **p<0.01 with respect to IL-1β control and aspirin alone. § p<0.05 with respect to Trolox C 
(10 µM) and IL-1β-treated control. # p<0.01 with respect to Trolox C (10 µM) and IL-1β-treated 
control. Statistical analysis was performed using one-way ANOVA followed by Student-Newman-
Keuls post-hoc test. Data are expressed as mean ± S.D. 
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Fig. 3. Lack of additive effect of ascorbic acid with the highly COX-2 inhibitor SC-58125 (A). 
Similarly, ascorbic acid (ASC) did not synergize with the non-selective COX inhibitor indomethacin 
(B). Cells were pre-incubated with the inhibitors at the indicated concentrations for 30 min and 
subsequently treated with IL-1β (10 U/ml) for 24 h. PGE2 in the supernatants was measured by an 
enzyme immunoassay. *p<0.05 and **p<0.01 with respect to IL-1β-treated control. Statistical 
analysis was performed using one-way ANOVA followed by Student-Newman-Keuls post-hoc test. 
Data are expressed as mean ± S.D. 
 
Fig. 4. IL-1β-induced synthesis of COX-2 in SK-N-SH cells is not affected by ascorbic acid and 
aspirin alone or in combination (Panel A). Cell lysates from untreated control cell cultures or cell 
cultures treated for 24 h with the indicated amounts of IL-1β (50 U/ml) alone or in combination with 
ascorbic acid and aspirin were separated by SDS-PAGE on a 7.5% acrylamide gel, blotted and 
incubated with antibodies against COX-1, COX-2 and actin.  Densitometric analysis of the blots is 
presented in Panel B.  
 
 
Fig. 5. Lack of effect of the combination of ascorbic acid and aspirin (A), different doses of ascorbic 
acid (B) and dehydroascorbic acid (DHA, C) on microsomal prostaglandin E synthase-1 (mPGES-1) 
expression. SK-N-SH cells were treated with IL-1β (10 U/ml) for 4 h in the absence or presence of 
different concentrations of ascorbic acid, aspirin or DHA. Total RNA was extracted and subjected to 
RT-PCR. 
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Fig. 6. Effect of ascorbic acid (ASC), dehydroascorbic acid (DHA), Trolox C (Panel A), aspirin and 
the combination of aspirin with ascorbic acid (Panel B), as well as the COX inhibitors indomethacin 
and SC-58125 (Panel C) on 8-isoprostaglandin F2α (8-iso-PGF2α) production in response to 10 U/ml 
IL-1β. 8-iso-PGF2α levels were quantitated in the culture medium 24 h following stimulation of SK-
N-SH cells with IL-1β alone, or in combination with the substances at the given concentrations. * 
p<0.05 and ** p<0.01 with respect to IL-1β alone. § p<0.05 with respect to aspirin alone, but not 
different from ascorbic acid alone. # p<0.05 with respect to ascorbic acid alone, and the 
corresponding dose of aspirin without ascorbic acid. Histogram represents mean ± S.D. of 3 
independent experiments. Statistical analysis was performed using one-way ANOVA followed by 
Student-Newman-Keuls post-hoc test. 
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